1. Newsroom
  2. The ins and outs of impact investing
Menu
Analysen 20.07.2020

The ins and outs of impact investing

The ins and outs of impact investing

Simon Pickard, Chairman of UBP’s Impact Investment Committee, and Kanini Mutooni, a member of UBP’s Impact Advisory Board, discuss impact investing, how COVID-19 has affected it and how it will evolve in the future.


The terms ESG, SRI and impact investing are often used interchangeably, and whilst there are indeed similarities and overlaps, the three investment approaches are quite distinct. Impact investing was born on the private equity markets but it is becoming increasingly important for public markets, and these can learn a lot from their private counterparts, especially from the perspective of achieving sustainable development goals.

The COVID-19 pandemic has thrown social vulnerabilities into sharp relief and today’s investors are keen to see their capital have an impact and generate innovation. This is particularly important in emerging markets, where impact investors can effect real change. However the biggest boost for impact investing can be found in the future: for the next generation, impact investing is a much more important and obvious approach to the markets.

Impact investing

Listen to our podcast now!


Simon_Pickard_150x150.jpg
Simon Pickard

Chairman of UBP’s Impact Investment Committee

Kanini.jpg
Kanini Mutooni

Member of UBP’s Impact Advisory Board


Auch lesenswert

Analysen 26.11.2021

The strong performance potential of Swiss small and mid-cap equities

The Swiss small- and mid-cap (also known as “SMID-cap”) universe offers a balanced and diversified exposure to companies with long-term value-creation potential. Active managers can create significant added value through a disciplined stock-selection process.

Analysen 22.11.2021

CRISPR: the implications of gene editing

In the latest episode of UBP’s Expert series, Norman Villamin, CIO Wealth Management and Pierre Corby, Equity Analyst Healthcare, invited Dr Samarth Kulkarni, CEO of CRISPR Therapeutics, to discuss the challenges and investment opportunities offered by medical innovation, specifically in the field of gene editing.

Analysen 19.11.2021

UBP Investment Outlook 2022

Embracing Change